




# MCMs for BURN INJURIES

**Narayan Iyer, Ph.D.**  
**Chief (Acting), MCM for Burn Injuries**  
**BARDA**

16 October 2014

# Threat & Scenario





Scenario

Demands



# Addressing the Treatment Bottleneck

## Current Situation





# Understanding Definitive Burn Care

## Thermal Burn Definitive Care Continuum

Days

Weeks

Months

Compatible with Concomitant Radiation Injury

Limit Burn Conversion  
Reduce Infection

Temporize Burns

Aid Debridement/ Excision

Enhance / Accelerate Healing of  
Autografts

Adjunct or Spare Autografts

Improve Functional  
Outcome

**Prevent DPT to FT conversion**  
Needs less grafting; quicker healing

**Faster & Easier Excision / Better visualization** –  
less morbidity; increase efficiency of the excision  
process

**Enhance**– more vascularized wound bed

**Accelerate**– Faster healing & wound  
closure

**Autograft sparing**- less morbidity, quicker  
healing



# Burn MCMs

## Considerations for Advanced Development



### Desired Characteristics

- **Address characteristics that expand use timeframe & capacity**
  - Ease of Use - Ability to 'Temporize' - Reduce Resource Burden
- **Create commercially sustainable solutions & *de facto* preparedness**
  - Adoptable into mainstream care - Multiple Indications - Amenable to VMI
- **Recognize CONOPS and focus on key aspects of definitive care**
  - Aid Debridement & excision - Deter Progression from DPT/ FT
  - Reduce Demand for Autograft - Lower Overall Cost of Burn Care

### Learn More

- **Background: Previous Special Instruction: BARDA-CBRN-BAA-12-100**
- [www.medicalcountermeasures.gov](http://www.medicalcountermeasures.gov) (links to current BAA)
- [www.fedbizopps.gov](http://www.fedbizopps.gov)
- **Email:** [narayan.iyer@hhs.gov](mailto:narayan.iyer@hhs.gov)



# BACK UP



# Primary Product Categories

## Definitive Care



Product Categories	Description
<b>Autologous Based Treatment Products</b>	<ul style="list-style-type: none"><li>• Products that utilize a patient's own skin cells to form a skin substitute or replacement.</li></ul>
<b>Natural Biological Products</b>	<ul style="list-style-type: none"><li>• Derived directly (or modified) from allogeneic or xenogeneic skin sources to provide a temporary skin substitute or skin replacement.</li></ul>
<b>Manufactured Biological Products</b>	<ul style="list-style-type: none"><li>• Derived from manufactured biomaterials or bioengineered cell lines, biological substitutes (allogeneic) to form a temporary skin substitute or skin replacement.</li></ul>
<b>Ancillary Products</b>	<ul style="list-style-type: none"><li>• Products that increase efficiency in procedures (faster, cheaper, broaden ease of use, increase throughput )</li></ul>